Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02741570 · ClinicalTrials.gov registry record · Phase 3
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 947
- Enrollment target
NCT02741570 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 947 participants.
The verdict
NCT02741570, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 947 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG Cetuximab/Erbitux
- DRUG Cisplatin/Platinol
- DRUG Carboplatin/Paraplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 947 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2022-09-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02741570
The ClinicalTrials.gov registry entry for NCT02741570 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 947 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT02741570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02741570 about?
NCT02741570 is a clinical study titled "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
What is the current status of trial NCT02741570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 947 participants. The study started on 2016-10-05. Estimated completion is 2022-09-22.
What interventions are being tested in trial NCT02741570?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Cetuximab/Erbitux (DRUG), Cisplatin/Platinol (DRUG), Carboplatin/Paraplatin (DRUG).
Who is sponsoring clinical trial NCT02741570?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.